Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer? | Zendy

Xiaoshen Zhang | Zendy; Yayi He | Zendy; Keyi Jia | Zendy; Rafał Dziadziuszko | Zendy; Sha Zhao | Zendy; Juan Deng | Zendy; Hao Wang | Zendy; Fred R. Hirsch | Zendy; Caicun Zhou | Zendy

Open Access

Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?

Author(s) -

Xiaoshen Zhang,

Yayi He,

Keyi Jia,

Rafał Dziadziuszko,

Sha Zhao,

Juan Deng,

Hao Wang,

Fred R. Hirsch,

Caicun Zhou

Publication year - 2019

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr.2019.09.20

Subject(s) - medicine , stage (stratigraphy) , lung cancer , oncology , value (mathematics) , cancer , statistics , mathematics , paleontology , biology

The immune status in the tumor micro-environment of lung cancer is highly informative, and expression status of some biomarkers in the tumor micro-environment may have deep connected statistical characteristics which could indicate immune status and predict related clinical outcomes. In this study, a panel of 9 immune biomarkers are selected for their possible predictive value of clinical outcomes in early-stage resectable non-small cell lung cancer (NSCLC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research